Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics. By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institutet – the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe disease, with profound implications for human health. Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University, Assistant Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs. Backed by Oxford Sciences Innovation and with a driven multidisciplinary team, Evox is building an exosome powerhouse focusing on the development of a modular platform for clinical translation of a broad range of exosome-based therapeutics. Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.
Location: United Kingdom, England, Oxford
Employees: 51-200
Total raised: $144.58M
Founded date: 2016
Investors 5
Date | Name | Website |
- | Oxford Uni... | innovation... |
- | OrbiMed | orbimed.co... |
- | Panacea Ve... | panaceaven... |
- | Oxford Sci... | oxfordscie... |
- | GV | gv.com |
Funding Rounds 3
Date | Series | Amount | Investors |
19.02.2021 | Series C | $96.92M | - |
22.03.2019 | - | $1.98M | - |
03.09.2018 | Series B | $45.68M | - |
Mentions in press and media 16
Date | Title | Description | Source |
20.02.2021 | Daily funding roundup - February 20th, 2021 | Recogni has raised $48.9M; Photomath secured $23M; Torii landed $10M; Pipe17 picks up $8M Highland ... | vator.tv/n... |
19.02.2021 | Biotech startup Evox Therapeutics lands £69.2M | Evox Therapeutics has raised £69.2 million in a Series C led by Redmile Group. The British startup m... | pitchbook.... |
18.02.2021 | Evox Therapeutics : completes £69.2 million Series C financi... | OXFORD, England, Feb. 18, 2021 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a le... | marketscre... |
18.02.2021 | Evox Therapeutics Closes £69.2M Series C Financing | Evox Therapeutics Ltd, an Oxford, UK-based exosome therapeutics company, raised £69.2m ($95.4m) in S... | finsmes.co... |
18.02.2021 | EVOX THERAPEUTICS COMPLETES £69.2 MILLION SERIES C FINANCING... | - | orbimed.co... |
18.01.2021 | John McHutchison joins the Board of Evox Therapeutics | OXFORD, England, Jan. 18, 2021 /PRNewswire/ -- Evox Therapeutics Ltd ("Evox" or the "... | marketscre... |
25.03.2019 | Term Sheet — Monday, March 25 | FINANCIAL SNACKS Robinhood, a no-fee trading stock trading startup, just made its first acquisition... | fortune.co... |
22.03.2019 | Evox Therapeutics Secures £1.5M in Funding from Innovate UK | Evox Therapeutics, an Oxford, England, UK-based exosome therapeutics company, secured £1.5m in fundi... | finsmes.co... |
04.09.2018 | Term Sheet — Tuesday, September 4 | IPO-BOUND Good morning, Term Sheet readers. Paid Content What you need to know about growing cyber... | fortune.co... |
04.09.2018 | Redmile, GV power exosome specialist Evox to £36M round | Evox Therapeutics has raised £35.5 million ($45.4 million) to support its pipeline of exosome-based ... | fiercebiot... |
Show more